Last reviewed · How we verify
NCT05254106: DETECT
The DETECT Project
trial testing Lower limb artery revascularization with paclitaxel-eluting device in Femoropopliteal Atheromatous Lesions in 250,000 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Nantes University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250,000 |
| Start date | 1 November 2011 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Lower limb artery revascularization with paclitaxel-eluting device
Conditions studied
- Femoropopliteal Atheromatous Lesions — all drugs for Femoropopliteal Atheromatous Lesions →
Sponsor
Nantes University Hospital
Who can join
18 and older, any sex, with Femoropopliteal Atheromatous Lesions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the all-cause mortality at 2 years of patients treated by a paclitaxel drug-eluting devices or non-drug-eluting devices after an endovascular femoropopliteal artery revascularization based on the French National Healthcare Data System (SNDS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease.
Wargny M, Leux C, Chatellier G, Coudol S, et al · · 2024 · cited 11× · PMID 38538200 · DOI 10.1016/j.jacc.2024.02.003
Verify or expand the search:
- PubMed search for NCT05254106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nantes University Hospital trials
Trials by the same sponsor.
- NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
- NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
- NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05254106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
- Last refreshed: 28 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing